Abstract 1590P
Background
International studies have highlighted the poor outcomes associated with cancer diagnosis following an emergency presentation (EP) to hospital. This study aims at assessing the rate of cancer patients newly referred to the Greater Paris University Hospitals (APHP) after an EP and the impact of EP on patient survival across various types of cancer.
Methods
A retrospective multicenter cohort study was conducted using the data warehouse of APHP. Consecutive patients newly referred with breast, lung, colon, rectum or pancreatic cancer between January 2019 and June 2022 were identified using claims data (ICD-10 codes). Comparative analyses between EP (diagnosis confirmed ≤30 days after emergency admission) and non-EP patients comprised in-hospital imaging, initial tumor staging from baseline PET/CT and CT-scan reports, and surgical treatment. Multivariable logistic regression was used to assess EP prevalence and its association with patient survival, adjusting for age, gender, diagnostic year (considering potential impacts of the COVID-19 pandemic), and cancer site. A Cox model was used to assess association of EP with survival, adjusting for the same factors and baseline metastatic status.
Results
The final cohort comprised 25,845 patients with 3,960 (15.3%) newly referred after an EP. EP patients exhibited higher rates of metastatic cancer (59% vs. 45%) and in-hospital imaging (53% vs. 31%), lower surgery rates (except for colon cancer patients) (18% vs 41%), and a higher risk to die within a year of diagnosis (49% vs 16%). Lung and pancreatic cancers were more frequent in EP than other cancer sites (20% and 23% respectively). The proportion of EP and non-EP patients was comparable during and after the COVID-19 pandemic, except for lung cancer. In the multivariable analysis, EP was strongly associated with age only for patients above 80 years of age (odds ratio: 3.1, 95% CI; 2.6-3.6). After adjusting for age and cancer site, patient mortality rate increased with EP referral (HR: 2.7, 95% CI 2.5-2.8).
Conclusions
Emergency presentation in a university hospital is a marker of poor outcome among newly referred cancer patients. Better coordination between hospitals and ambulatory health care networks is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10